Results 111 to 120 of about 18,037 (235)

Investigating the efficacy of mineralocorticoid receptor antagonists for cardiovascular outcomes in different diseases

ESC Heart Failure
Aims Mineralocorticoid receptor antagonists (MRAs) are crucial in managing cardiovascular diseases, with different MRAs demonstrating varying efficacy across diverse disease contexts. This research aims to compare the cardiovascular protective effects of
Jiao Wang, Meijuan Zheng, Yuchun Yang, Lei Zhang, Muhuyati Wulasihan   +4 more
doaj   +1 more source

Cardiovascular Outcomes of Insulin Degludec Versus Insulin Glargine in Trial‐Eligible and Ineligible Populations: A DEVOTE‐Inspired Target Trial Emulation Using the Swedish National Diabetes Register

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To compare cardiovascular outcomes associated with the initiation of insulin degludec versus insulin glargine using a target trial emulation approach in nationwide real‐world data. Materials and Methods We conducted a nationwide observational cohort study using Swedish health registers, including the National Diabetes Register ...
Thomas Nyström, Jens Michelsen, Henrik Imberg, Sara Hallström, Viktor Tasselius, Anna Norhammar, Max Petzold, Julia K. Mader, Pratik Choudhary, Manal K. Elzalabany, Jonathan Valabhji, Shivani Misra, Safoora Gharibzadeh, Puriya Daniel Würtz Yazdanfard, Kathrine Kold Sørensen, Christian Torp‐Pedersen, Marcus Lind   +16 more
wiley   +1 more source

Dose–Exposure–Response Analysis of Finerenone on Serum Potassium and Cardiovascular Outcomes Among Patients With Heart Failure: Insights From FINEARTS‐HF

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Finerenone reduces the risk of heart failure and cardiovascular (CV) death among patients with heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF). Whether the effects of finerenone to reduce CV risk are dose/exposure dependent is not clear.
Thomas Eissing, Finnian R. Mc Causland, Muthiah Vaduganathan, Sebastiaan C. Goulooze, Eleonora Marostica, Jan Berkhout, Paul van den Berg, Nelleke Snelder, Dirk Garmann, Joerg Lippert, Meike Brinker, Brian L. Claggett, John J. V. McMurray, Scott D. Solomon   +13 more
wiley   +1 more source

Clinical Characteristics, Effectiveness and Safety Outcomes in Chinese Patients With Chronic Kidney Disease and Type 2 Diabetes Who Initiated Finerenone: A Retrospective Real‐World Cohort Study From the FOUNTAIN Platform

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Finerenone was approved in China in 2022 for adult patients with chronic kidney disease (CKD) associated with Type 2 diabetes (T2D). This study aimed to characterize Chinese patients with CKD and T2D who initiated finerenone in routine clinical practice and to evaluate treatment outcomes.
Yan Kong, Bei Sun, Chunyan Shan, Zhe Xu, Hui Yang, Nikolaus G. Oberprieler, Huan Wei, Liming Chen   +7 more
wiley   +1 more source

Nonsteroidal Mineralocorticoid Receptor Antagonist (Finerenone) in Cardiorenal Disease. [PDF]

J Clin Med, 2023
Shah M, Awad AS, Abdel-Rahman EM.
europepmc   +1 more source

At the heart of home‐based care: multidisciplinary heart failure management in a quaternary centre's community programmes

Internal Medicine Journal, EarlyView.
Abstract Background Heart failure (HF) is a frequent cause of hospital admissions, carrying a high risk of hospital readmission and mortality. Alfred Health General Medicine Hospital in the Home (GM‐HITH) and Hospital Admission Risk Program (HARP) offer multidisciplinary HF care to multimorbid patients in bed‐substitution and non‐admitted community ...
Elana Forbes, Ingrid Hopper, Cathy Corbett, Felice Borghmans, Emma O'Donnell, Ana Slavnic, Genevieve Harvey, Elizabeth Rochford, Archana Thayaparan   +8 more
wiley   +1 more source

Semaglutide in type 2 diabetes and chronic kidney disease in Australia: practical clinical considerations from a multidisciplinary panel

Internal Medicine Journal, EarlyView.
Abstract Chronic kidney disease (CKD) and cardiovascular disease (CVD) are major causes of morbidity and mortality in people with type 2 diabetes (T2D). Contemporary CKD guidelines increasingly support incorporation of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) as an additional pillar of cardiorenal therapy alongside renin–angiotensin ...
Eugenia Pedagogos, Roger Chen, Adam Nelson, Sunil Badve, Roy Rasalam, Richard MacIsaac   +5 more
wiley   +1 more source

Pulmonary Vein Isolation Alone Versus Adjunctive Ablation for Paroxysmal Atrial Fibrillation

Journal of Cardiovascular Electrophysiology, EarlyView.
Clinical Outcomes of Pulmonary Vein Isolation Alone Versus Additional Lesion Sets in Paroxysmal Atrial Fibrillation ABSTRACT Background Pulmonary vein isolation (PVI) is the standard ablation strategy for paroxysmal atrial fibrillation (PAF). Despite guideline recommendations favoring PVI alone in PAF, some operators routinely perform extra pulmonary ...
Michel Abou Khalil, Christian M. Massad, Eli Tsakiris, William Herbst, Maximilian Moersdorf, Mohammad Montaser Atasi, Yara Menassa, Alex El Darzi, Carlo El Khoury, Ghassan Bidaoui, Hadi Younes, Yishi Jia, Rodolfo Montiel, Amitabh Pandey, Han Feng, Qussay Marashly, Nassir F. Marrouche, Omar Kreidieh   +17 more
wiley   +1 more source

Temporal Association Between Intrathoracic Impedance and Tachyarrhythmia Occurrence

Journal of Cardiovascular Electrophysiology, EarlyView.
A decrease in intrathoracic impedance is temporally associated with subsequent AF occurrence and, at the episode level, with a shorter time to VT. These findings suggest that daily intrathoracic impedance may provide information on short‐term changes preceding tachyarrhythmia occurrence.
Monika Butkuvienė, Andrius Petrėnas, Andrius Sološenko, Anneli Olsson, Rasmus Borgquist, Pyotr G. Platonov   +5 more
wiley   +1 more source

Mineralocorticoid Receptor Antagonist Use in Contemporary Heart Failure Care. [PDF]

Card Fail Rev
Bruno J, Mebazaa A, Moura LZ, Čelutkienė J, Sindone A, Rosano G.   +5 more
europepmc   +1 more source